Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4754387 | 0.96 | SMN1; SMN2 (0.39) | SMN1; SMN2CHRM5CHRM3 | |
| SCHEMBL9081019 | 0.79 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL12650558 | 0.78 | MEN1 (0.31) | SMN1; SMN2MEN1KMT2AOPRD1 | |
| SCHEMBL8806059 | 0.77 | SMN1; SMN2 (0.35) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5731936 | 0.75 | MEN1 (0.34) | SMN1; SMN2CHRM5CHRM3MEN1KMT2A | |
| SCHEMBL538775 | 0.75 | MEN1 (0.34) | SMN1; SMN2CHRM5CHRM3MEN1KMT2A | |
| SCHEMBL1473655 | 0.75 | MEN1 (0.34) | SMN1; SMN2CHRM5CHRM3MEN1KMT2A | |
| SCHEMBL11362053 | 0.74 | ALDH1A1 (0.37) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5617 | 0.74 | — | — | |
| SCHEMBL8373239 | 0.74 | SMN1; SMN2 (0.38) | SMN1; SMN2CHRM5CHRM3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389716-B2 | Process for the synthesis of quetiapine | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2013-03-05 | — | — | US | claimed |
| US-20110118460-A1 | PROCESS FOR THE SYNTHESIS OF QUETIAPINE | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2011-05-19 | — | — | US | claimed |
| WO-2006027789-A1 | PROCESS FOR PRODUCING 11-[4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL]DIBENZO[b,f][1,4]THIAZEPINE AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | JUBILANT ORGANOSYS LIMITED (IN) | 2006-03-16 | — | — | WO | claimed |
| EP-1102789-A1 | MONOCYCLIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTION AND COMPOSITIONS CONTAINING THEM | Menarini Ricerche S.p.A. (IT) | 2001-05-30 | — | — | EP | claimed |
| WO-2000008046-A1 | MONOCYCLIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTION AND COMPOSITIONS CONTAINING THEM | MENARINI RICERCHE S.P.A. (IT) | 2000-02-17 | — | — | WO | claimed |
| EP-0240228-B1 | THIAZEPINE COMPOUNDS | ICI AMERICAS INC. (US) | 1990-11-07 | — | — | EP | claimed |
| US-12584083-B2 | Surface treatment composition, surface treatment method, and method for producing semiconductor substrate | FUJIMI INCORPORATED (JP) | 2026-03-24 | — | — | US | disclosed |
| EP-4606929-A1 | ETCHING SOLUTION, REPLENISHMENT SOLUTION, AND METHOD FOR FORMING COPPER WIRING | MEC Company Ltd. (JP) | 2025-08-27 | — | — | EP | disclosed |
| US-20240124810-A1 | SURFACE TREATMENT COMPOSITION, SURFACE TREATMENT METHOD, AND METHOD FOR PRODUCING SEMICONDUCTOR SUBSTRATE | FUJIMI INCORPORATED (JP) | 2024-04-18 | — | — | US | disclosed |
| CN-117778117-A | Surface treatment composition, surface treatment method, and method for manufacturing semiconductor substrate | 福吉米株式会社 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023140146-A1 | POLISHING COMPOSITION, CONCENTRATED SOLUTION OF POLISHING COMPOSITION, AND POLISHING METHOD | 株式会社フジミインコーポレーテッド | 2023-07-27 | — | — | WO | disclosed |
| CN-113179590-A | Etching solution, replenishment solution, and method for forming copper wiring | MEC股份有限公司 | 2021-07-27 | — | — | CN | disclosed |
| CN-107208279-B | Etching solution, replenishment solution, and method for forming copper wiring | MEC股份有限公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-0757670-A1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| WO-1996041795-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-27 | — | — | WO | disclosed |
| WO-1995029152-A1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-02 | — | — | WO | disclosed |
| EP-0625997-A1 | DIAMINOCARBONATE COMPOUNDS AND THEIR USE AS CATALYSTS. | RWE DEA AG (DE) | 1994-11-30 | — | — | EP | disclosed |
| WO-1993016124-A1 | DIAMINOCARBONATE COMPOUNDS AND THEIR USE AS CATALYSTS | RWE-DEA Aktiengesellschaft für Mineraloel und Chemie (DE) | 1993-08-19 | — | — | WO | disclosed |
| US-4879288-A | Novel dibenzothiazepine antipsychotic | ICI AMERICAS INC. (US) | 1989-11-07 | — | — | US | disclosed |
| US-4097597-A | ANTISCHIZOPHRENICS | ABBOTT LABORATORIES (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584083-B2 | Surface treatment composition, surface treatment method, and method for producing semiconductor substrate | PIEZO1, TYRO3, ACP1 | SMN1; SMN2 1007/4885CHRM5 142/4885CHRM3 214/4885 |
| US-20110118460-A1 | PROCESS FOR THE SYNTHESIS OF QUETIAPINE | CYP4F11, MAOB, CYP2F1 | SMN1; SMN2 4797/4885CHRM5 1606/4885CHRM3 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.